Cetuximab News and Research

RSS
Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.
Mutations in the targets of designer drugs critically influence their effectiveness

Mutations in the targets of designer drugs critically influence their effectiveness

Cetuximab (Erbitux) can battle cancer and prolong life in many patients with advanced colorectal cancer

Cetuximab (Erbitux) can battle cancer and prolong life in many patients with advanced colorectal cancer

Radiotherapy with cetuximab significantly improves disease control and survival in head and neck cancer

Radiotherapy with cetuximab significantly improves disease control and survival in head and neck cancer

Acne-like rash linked to effectiveness of new targeted cancer treatment – cetuximab

Acne-like rash linked to effectiveness of new targeted cancer treatment – cetuximab

ImClone quarterly sales reach $71.4 Million

ImClone quarterly sales reach $71.4 Million

Erbitux (cetuximab) combined with irinotecan offers another option for patients who have colorectal cancer

Erbitux (cetuximab) combined with irinotecan offers another option for patients who have colorectal cancer

A second-generation targetted antibody for potential cancer therapy

A second-generation targetted antibody for potential cancer therapy